¶¶Òõ¶ÌÊÓƵ

The PHYSPHAR team investigates the mechanisms of atherosclerotic plaque instability and cardiac dysfunction using integrated experimental models, with the aim of identifying key molecular pathways and developing novel therapies for plaque stabilization and heart failure.

Two research groups of the CDS lab are part of Infla-Med Centre of Excellence. The Ferroptosis Signalling group investigates the role of ferroptosis in critical illnesses, organ injury, vascular disease, and cancer, with the aim of developing innovative diagnostics and therapeutic strategies. And the Pyroptosis Inflammasome Signalling group investigates inflammasome-mediated pyroptosis in immune responses, focusing on its role in infectious and auto-inflammatory diseases to uncover underlying mechanisms and identify new therapeutic targets.

The Laboratory of Experimental Medicine and Pediatrics (LEMP) research focuses on inflammation in clinically relevant contexts through interdisciplinary, translational approaches combining experimental and clinical research. Using advanced models and technologies (e.g. organoids, omics, and clinical trials), the team investigates mucosal barrier dysfunction in inflammatory and infectious diseases. A key focus is the role of transmembrane mucins and their genetic diversity in epithelial signalling and disease progression.

LMPH aims to develop innovative therapeutics, diagnostics, and vaccines through multidisciplinary, translational research. It focuses on understanding host–pathogen interactions, identifying novel targets and resistance mechanisms, and addressing factors underlying treatment and vaccine failure. In parallel, it explores next-generation diagnostics and vaccine strategies for improved disease detection, monitoring, and prevention.

UAMC medicinal chemistry focuses on inflammation, cell death, and infectious diseases, developing chemical tools to validate novel targets and generate hit to lead compounds. The teams integrate advanced computational approaches, including free energy perturbation, QM/MM simulations, and chemoinformatics driven SAR, to accelerate drug discovery.

The Laboratory of Medical Biochemistry (LMB) investigates structure–function relationships of proteins relevant to human disease, combining expertise in protein production, functional assays, and structural biology. The group integrates biophysical and crystallographic approaches with broader experience in molecular interactions involving proteins, small molecules, peptides, nucleic acids, and lipids.